We expect that tissue Type D will be approximately half of our tissue samples. We propose to bank excess tissue from these unconsented cases, with the Tissue Bank having an "honest broker" role to protect identifiers, request a waiver of informed consent, and only release Type D samples as identified samples. We expect that it will be logistically impossible to have all patients who undergo surgical procedures (or proper next-of-kin in the case of autopsy samples) be adequately informed of the tissue banking initiative. This category of excess tissue samples will have linkage to individual patients of origin in order that the bank can confirm diagnosis or update the relevant medical information of individual specimens. This is consistent with banking policies at other institutions including federal agencies such as NIH and NCI and is based on the concept that an IRB can support the "honest broker" concept of a tissue bank to protect the identities of patients. Examples of this type of tissue would be routine specimens such as gall bladders or reduction mammoplasties. It may be impractical to obtain consent from such cases and they would not likely be part of a larger organ based research project (i.e. Type B), yet valuable research could be done if we had a collection of samples that are always dispensed as de-identified samples without potential harm to individual patients. From the perspective of research, those seeking to do outcomes studies would not want to study fully anonymous samples, but a great deal of work can and is done across the nation with de-identified tissue samples that have IRB oversight allowing the Tissue Bank an honest broker role that increases the value of the individual samples.